Journal

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Read time: 1 mins

Published:1st Oct 2023

Author: Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R et al.

Source: Neurology and Therapy

Availability: Free full text

Ref.:Neurol Ther. 2023 Oct;12(5):1435-1438.

DOI:10.1007/s40120-023-00514-4

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis (MP4 594600 KB).

Read abstract on library site Access full article